medigraphic.com
Instituto Nacional de Salud Pública

2015, Number S2

<< Back Next >>

salud publica mex 2015; 57 (S2)

Antiretroviral therapy delay initiation in Mexico

Magis-Rodríguez CL, Villafuerte-García A, Cruz-Flores RA, Uribe-Zúñiga P

Language: Spanish
References: 27
Page: 127-134
PDF size: 346.98 Kb.


ABSTRACT

Objective. To estimate the prevalence of delayed- initiation (DI) of antiretroviral therapy (ART) for people with HIV attended at the Ministry of Health (SS, for its initials in Spanish) in Mexico, and to describe its behavior over time (2008-2013) and differences by gender and age. Materials and methods. Descriptive and sectional study of people entering ART in the period 2008-2013 in the SS. The prevalence of DI ART (CD4+ ‹200 cells/ml) was estimated and differences according to sex and age were analyzed. Results. The DI ART prevalence was 49%, having decreased 10% in the period. In men was 4.8% and 24.5% in women (p‹0.01). The 15 to 29 years group also showed a decrease. Conclusions. Despite the decrease in ART DI prevalence, it still remains high. It is necessary to generate comprehensive screening strategies with multisectoral participation.


REFERENCES

  1. Palella Jr FJ, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003;138:620-626.

  2. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005;39 (4):446-453.

  3. Girardi E, Sabin AC, D´Arminio MA. Late Diagnosis of HIV Infection: Epidemiological Features, Consequences and Strategies to Encourage Earlier Testing. J Acquir Immune Defic Syndr 2007; 46 (1): S3-S8.

  4. Smith RD, Delpech VC, Brown AE, Rice DB. HIV Transmission and high rates of late diagnosis among adults aged 50 years and over. AIDS 2010; 24(13):2109-2115.

  5. Iwuji C, Churchill D, Gilleece Y, Weiss HA, Fisher M. Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study. BMC Public Health 2013;13:397.

  6. Celesia BM, Castronuovo D, Pinzone MR, Bellissimo F, Mughini MT, Lupo G, et al. Late presentation of HIV infection: predictors of delayed diagnosis and survival in Eastern Sicily. Eur Rev Med Pharmacol Sci 2013;17(16):2218-2224.

  7. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral and revised recommendations for HIV screening of pregnant women. MMWR 2001;50(No. RR-19):1-81.

  8. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. European Late Presenter Consensus Working Group. Late presentation of HIV infection: a consensus definition. HIV Med 2011;12:61-64.

  9. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011;12(1):61-64.

  10. Rurangirwa J, Bingham AT, Kim J, Hu WY, Bing E. Late HIV detection among adult males in Los Angeles County, 2000-2004. AIDS Care 2013;25(4):481-487.

  11. Crabtree-Ramírez B, Caro-Vega Y, Belaunzarán-Zamudio F, Sierra- Madero J. High prevalence of late diagnosis of HIVin Mexico during the HAART era. Salud Publica Mex 2012;54(5).

  12. Secretaría de Salud. Programa Nacional para la Prevención y el control del VIH y el sida; Sistema de Administración, Logística y Vigilancia de ARV, 2014 [consultado el 27de febrero de 2014]. Disponible en: http://salvar. salud.gob.mx

  13. Scognamiglio P, Chiaradia G, De Carli G, Guiliani M, Mastroianni CM, Barbacci S, et a . The pontencial impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnsosis. BMC Infectious Disease 2013;13:473.

  14. Oliva J, Galindo S, Vives N, Arriaga A, Izquierdo A, Nicolau A, et al. Retraso diagnóstico de la infección por el virus de la inmunodeficiencia humana en España. Enferm Infecc Microbiol Clin 2010;28(9):583-589.

  15. Klein D, Hurley BL, Merrill D, Quesenberry PC. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: Implications for early detection. J Acquir Immune Defic Syndr 2003;32 (2):143-152.

  16. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for Human Immunodeficiency Virus care in the United States and Canada. Clin Infect Dis 2010;50(11):1512-1520.

  17. Crabtree-Ramírez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Padgett D, et al. (2011) Cross-sectional analysis of late HAARTiInitiation in Latin America and the Caribbean: Late testers and late presenters. PLoS ONE 6(5): e20272. doi:10.1371/journal.pone.0020272

  18. Centro Nacional para la Prevención y el Control del VIH y el Sida, Boletín del Grupo de Información Sectorial en VIH/sida, 2012, 10. Consultado en: http://www.censida.salud.gob.mx/descargas/comites/monitoreo/ Bol10_v2012_19122013.pdf

  19. Herrera C, Campero L. La vulnerabilidad e invisibilidad de las mujeres ante el VIH/sida: constantes y cambios en el tema. Salud Publica Mex 2002;44(6):554-564.

  20. Torres P, Walker D, Gutiérrez JP, Bertozzi S. Estrategias novedosas de prevención de embarazos e ITS/VIH/Sida entre adolescentes escolarizados mexicanos Salud Publica Mex 2006;48(4):308-316.

  21. Gutiérrez JP, Sucilla-Pérez H, Conde-González CJ, Izazola JA, Romero- Martínez M, Hernández-Ávila M. Seroprevalencia de VIH en población mexicana de entre 15 y 49 años: resultados de la Ensanut 2012. Salud Publica Mex 2014;56 (4):323-332.

  22. Gayet C, Magis C, Sacknoff D, Guli L. Prácticas sexuales de las poblaciones vulnerable a la epidemiología de VIH/SIDA en México. México: Ángulos del SIDA, 2007.

  23. Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS 2001;15(1):17-85.

  24. Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIVpositive persons in Europe: Results from the collaboration of observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013;10(9).

  25. Kirschner D, Webb G, Cloyd M. Model of HIV-1 disease progression based on virus induced lymph node homing and hominginduced apoptosis of CD4 lymphocytes. J Acquir Immune Defic Syndr 2000;24 (4):352-362.

  26. Grabmeier-Pfistershammer K, Rieger A, Schröck T, Schlag M. Economic burden of late presentation in HIV disease in Austria: a comparison of the initial costs imposed by advanced HIV disease vs. non-late presentation. Cent Eur J Med 2013;125(13-14):402-407.

  27. Abaasa A, Todd J, Ekour K, Kalyango JN, Levin J, Odeke E, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Services Research 2008;8:241.




2020     |     www.medigraphic.com